Large interest in OXC-201 at the IPF Summit in Boston

There was a lot of interest in Oxcias poster describing OXC-201, the promising novel treatment strategy for Idiopathic pulmonary fibrosis (IPF), at the IPF summit in Boston 29th of August to 1st of September.

Christina Kalderén explaining the exciting data of OXC-201 for IPF Summit delegates.

A new treatment is desperately needed. Idiopathic pulmonary fibrosis (IPF) is a condition in which the lungs become scarred and breathing becomes increasingly difficult. More people die from pulmonary fibrosis than some well-known types of cancer, but few people have ever heard of the disease. Patients face tough challenges due to slow diagnosis and difficulties in accessing treatments and supportive care. It is vital to find effective treatments that improve symtoms and increase survival. Awareness and priority of the disease need to be heightened and September 2022 has in fact been selected as Pulmonary Fibrosis awareness month.